Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate -to -Severe Plaque Psoriasis

Background: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-tosevere plaque psoriasis. This report describes real-world effectiveness and safety of tildrakizumab through 64 weeks of treatment. Methods: In this Phase 4, multicenter, uncontrolled, open -label trial (NCT03718299), adults with moderate-to-severe plaque psoriasis received tildrakizumab 100 mg at weeks 0 and 4 and every 12 weeks thereafter through week 52. Effectiveness was assessed from body surface area (BSA) affected and static Physician Global Assessment (sPGA) through week 64 and Psoriasis Area and Severity Index (PASI) through week 52. Adverse events are reported. Results: Of 55 patients enrolled, 45 completed the study and 36 received all doses of tildrakizumab. From baseline to week 64, mean standard deviation BSA decreased by 83.1% (from 14.5 11.5 to 2.1 3.6) and sPGA by 67.6% (from 3.2 0.6 to 1.0 1.0); sPGA x BSA decreased by 89.6% (from 47.0 41.5 to 4.6 9.4; all P<0.001). PASI scores decreased compared to baseline at weeks 4, 16, 28, and 52 (P<0.001). For PASI responses at week 52 compared with baseline, 87.0% achieved.75% improvement, 56.5% achieved 90% improvement, and 32.6% achieved 100% improvement. Of 85 treatment-emergent adverse events in 34/55 patients, none were considered related to tildrakizumab treatment. Conclusions: Tildrakizumab treatment was effective in adult patients with moderate-to-severe plaque psoriasis in real -world settings, with no new safety signals.